These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 24065086)

  • 1. Correlation and prognostic value of osteopontin and Bcl-2 in hepatocellular carcinoma patients after curative resection.
    Deng B; Zhang XF; Zhu XC; Huang H; Jia HL; Ye QH; Dong QZ; Qin LX
    Oncol Rep; 2013 Dec; 30(6):2795-803. PubMed ID: 24065086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma.
    Pan HW; Ou YH; Peng SY; Liu SH; Lai PL; Lee PH; Sheu JC; Chen CL; Hsu HC
    Cancer; 2003 Jul; 98(1):119-27. PubMed ID: 12833464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative analysis of apoptosis-related gene expression in hepatocellular carcinoma.
    Ikeguchi M; Hirooka Y; Kaibara N
    Cancer; 2002 Nov; 95(9):1938-45. PubMed ID: 12404288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteopontin promoter polymorphisms at locus -443 significantly affect the metastasis and prognosis of human hepatocellular carcinoma.
    Dong QZ; Zhang XF; Zhao Y; Jia HL; Zhou HJ; Dai C; Sun HJ; Qin Y; Zhang WD; Ren N; Ye QH; Qin LX
    Hepatology; 2013 Mar; 57(3):1024-34. PubMed ID: 23079960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrence and poor prognosis following resection of small hepatitis B-related hepatocellular carcinoma lesions are associated with aberrant tumor expression profiles of glypican 3 and osteopontin.
    Yu MC; Lee YS; Lin SE; Wu HY; Chen TC; Lee WC; Chen MF; Tsai CN
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S455-63. PubMed ID: 21822558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Identification of metastasis-related osteopontin expression and glycosylation in hepatocellular carcinoma].
    Sun HY; Li Y; Guo K; Kang XN; Sun C; Liu YK
    Zhonghua Gan Zang Bing Za Zhi; 2011 Dec; 19(12):904-7. PubMed ID: 22525502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of osteopontin and CD44s expression for patients with hepatocellular carcinoma undergoing liver transplantation or resection.
    Beckebaum S; Chen X; Sotiropoulos GC; Radtke A; Daoudaki M; Baba HA; Wohlschlaeger J; Broelsch CE; Gerken G; Cicinnati VR
    Transplant Proc; 2008 Nov; 40(9):3182-4. PubMed ID: 19010227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of osteopontin with peritumoral infiltrating macrophages is associated with poor prognosis of early-stage hepatocellular carcinoma after curative resection.
    Zhu W; Guo L; Zhang B; Lou L; Lin Z; Zhu X; Ren N; Dong Q; Ye Q; Qin L
    Ann Surg Oncol; 2014 Apr; 21(4):1304-13. PubMed ID: 24366422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteopontin, a single marker for predicting the prognosis of patients with tumor-node-metastasis stage I hepatocellular carcinoma after surgical resection.
    Chen RX; Xia YH; Cui JF; Xue TC; Ye SL
    J Gastroenterol Hepatol; 2010 Aug; 25(8):1435-42. PubMed ID: 20659235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteopontin combined with CD44, a novel prognostic biomarker for patients with hepatocellular carcinoma undergoing curative resection.
    Yang GH; Fan J; Xu Y; Qiu SJ; Yang XR; Shi GM; Wu B; Dai Z; Liu YK; Tang ZY; Zhou J
    Oncologist; 2008 Nov; 13(11):1155-65. PubMed ID: 18997126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postoperative serum osteopontin level is a novel monitor for treatment response and tumor recurrence after resection of hepatitis B-related hepatocellular carcinoma.
    Zhou C; Zhou HJ; Zhang XF; Lou LL; Ye QH; Zheng Y; Wang J; Zhu HT; Dong QZ; Jia HL; Zhu WW; Guo L; Zhao Y; Gao DM; Qin LX
    Ann Surg Oncol; 2013 Mar; 20(3):929-37. PubMed ID: 23203407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spatial localization of the JAG1/Notch1/osteopontin cascade modulates extrahepatic metastasis in hepatocellular carcinoma.
    Xue TC; Zou JH; Chen RX; Cui JF; Tang ZY; Ye SL
    Int J Oncol; 2014 Nov; 45(5):1883-90. PubMed ID: 25176314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of osteopontin in hepatitis B virus-related hepatocellular carcinoma.
    Xie H; Song J; Du R; Liu K; Wang J; Tang H; Bai F; Liang J; Lin T; Liu J; Fan D
    Dig Liver Dis; 2007 Feb; 39(2):167-72. PubMed ID: 17161983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Interference of osteopontin expression inhibits the invasion and metastasis of human hepatocellular carcinoma cell lines].
    Lin F; Li YY; Xia JT; Wen MJ; Lai YY; Cai WS; Wu ZF; Fan SF
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jun; 17(6):422-5. PubMed ID: 19567019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C-C chemokine receptor type 1 mediates osteopontin-promoted metastasis in hepatocellular carcinoma.
    Zhu Y; Gao XM; Yang J; Xu D; Zhang Y; Lu M; Zhang Z; Sheng YY; Li JH; Yu XX; Zheng Y; Dong QZ; Qin LX
    Cancer Sci; 2018 Mar; 109(3):710-723. PubMed ID: 29285854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down-regulation of osteopontin inhibits metastasis of hepatocellular carcinoma cells via a mechanism involving MMP-2 and uPA.
    Chen RX; Xia YH; Xue TC; Zhang H; Ye SL
    Oncol Rep; 2011 Mar; 25(3):803-8. PubMed ID: 21174062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteopontin promotes hepatocellular carcinoma invasion by up-regulating MMP-2 and uPA expression.
    Chen RX; Xia YH; Xue TC; Ye SL
    Mol Biol Rep; 2011 Aug; 38(6):3671-7. PubMed ID: 21104439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Segment-specific targeting via RNA interference mediates down-regulation of OPN expression in hepatocellular carcinoma cells.
    Lin F; Huang CM; Cao J; Pei ZH; Gu WL; Fan SF; Li KP; Lin CM
    Genet Mol Res; 2015 Nov; 14(4):14440-7. PubMed ID: 26600502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombin is a therapeutic target for metastatic osteopontin-positive hepatocellular carcinoma.
    Xue YH; Zhang XF; Dong QZ; Sun J; Dai C; Zhou HJ; Ren N; Jia HL; Ye QH; Qin LX
    Hepatology; 2010 Dec; 52(6):2012-22. PubMed ID: 20890897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metastasis-related miR-185 is a potential prognostic biomarker for hepatocellular carcinoma in early stage.
    Zhi Q; Zhu J; Guo X; He S; Xue X; Zhou J; Hu B; Li H; Chen S; Zhao H; Kuang Y
    Biomed Pharmacother; 2013 Jun; 67(5):393-8. PubMed ID: 23648054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.